VERTEX PHARMACEUTICALS INC / MA (VRTX) Operating cash flow 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$3.6BFY2025 · since FY2016: $236.1M → $3.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.6B | +837.2% |
| FY2024 | -$492.6M | -113.9% |
| FY2023 | $3.5B | -14.3% |
| FY2022 | $4.1B | +56.2% |
| FY2021 | $2.6B | -18.7% |
| FY2020 | $3.3B | +107.3% |
| FY2019 | $1.6B | +23.5% |
| FY2018 | $1.3B | +50.3% |
| FY2017 | $844.9M | +257.9% |
| FY2016 | $236.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Gross marginVRTX Operating incomeVRTX Operating marginVRTX Free cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →